Motivational Interviews Based on the Five-Step (5A) Model on Obesity Risk

August 12, 2026 updated by: Simay Hiçyılmaz, Istinye University

The Effect of Structured Motivational Interviews Based on the Five-Step (5A) Model on Behavioral Change in Individuals at High Risk of Obesity in Family Medicine: A Mixed-Methods Randomized Controlled Trial Study Protocol

The goal of this clinical trial is to learn if a structured motivational interviewing program based on the Five-Step (5A) model works to promote healthy lifestyle behaviors in individuals at high risk of obesity. It will also learn about the effects on anthropometric measurements and physical activity levels. The main questions it aims to answer are:

  • Does this structured program promote healthy lifestyle behaviors in individuals at high risk of obesity?
  • To what extent does it increase participants' intrinsic motivation and readiness for behavioral change?

Participants will:

  • Attend structured interview sessions throughout the designated process
  • Visit the clinic at regular intervals for follow-up and evaluations
  • Record their lifestyle changes, physical activity levels, and experiences throughout the process

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
    • Ümraniye
      • Istanbul, Ümraniye, Turkey (Türkiye)
        • Ümraniye No.19 Family Health Center
        • Principal Investigator:
          • Simay Hiçyılmaz, MD, PhD Candidate

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged:18-64 years,
  • Body Mass Index (BMI): 25.0-35.0 kg/m² (Overweight or Class I Obesity)
  • Literate,
  • Voluntary agreement to participate.

Exclusion Criteria:

  • Body Mass Index (BMI): >35.0 kg/m²,
  • Active involvement in a concurrent weight loss program,
  • Current use of anti-obesity medication,
  • Severe psychiatric or cognitive disorders,
  • Pregnancy,
  • Missing more than one motivational interview session,
  • Orthopedic conditions precluding physical activity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
Experimental Group: Participants receive five structured motivational interviewing sessions over a three-month intervention period, with anthropometric measurements repeated at each session.
Behavioral: Motivational Interviewing
Motivational Interviewing Techniques and the Five-Step (5A) Model Framework
No Intervention: Control Group
Control Group: Participants are monitored with standard routine care over a three-month intervention period without motivational interviewing sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Body Mass Index (BMI)
Time Frame: Until the end of five motivational interviews that will take place over a three-month period
Changes in body mass index measured in kg/m² from baseline to the end of the intervention period.
Until the end of five motivational interviews that will take place over a three-month period
Change in Body Weight
Time Frame: Until the end of five motivational interviews that will take place over a three-month period
Changes in body weight measured in kilograms (kg) from baseline to the end of the intervention period.
Until the end of five motivational interviews that will take place over a three-month period
Change in Waist Circumference
Time Frame: Until the end of five motivational interviews that will take place over a three-month period
Changes in waist circumference measured in centimeters (cm) from baseline to the end of the intervention period.
Until the end of five motivational interviews that will take place over a three-month period
University of Rhode Island Change Assessment (URICA) Scale Score
Time Frame: Until the end of five motivational interviews that will take place over a three-month period
Changes in readiness score measured by the 32-item University of Rhode Island Change Assessment (URICA) scale. Each item is rated on a 5-point Likert scale ranging from 1 to 5, where higher scores indicate greater readiness for change.
Until the end of five motivational interviews that will take place over a three-month period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Physical Activity Level
Time Frame: Until the end of five motivational interviews that will take place over a three-month period.
Changes in physical activity levels measured by the General Practice Physical Activity Questionnaire (GPPAQ) instrument from baseline to the end of the intervention period, categorizing participants into four activity levels (active, moderately active, moderately inactive, and inactive) based on occupational physical activity and exercise/cycling hours.
Until the end of five motivational interviews that will take place over a three-month period.
Qualitative Assessment of Motivational Factors
Time Frame: Until the end of five motivational interviews that will take place over a three-month period.
Qualitative themes encompassing awareness, motivational barriers, health responsibility, and self-efficacy assessed via in-depth interviews.
Until the end of five motivational interviews that will take place over a three-month period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istinye University

Investigators

  • Study Director: Gülhan Kalmuk, Assist. Prof. Dr., Istinye University
  • Principal Investigator: Simay Hiçyılmaz, MD, PhD Candidate, Istinye University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

August 9, 2026

First Submitted That Met QC Criteria

August 12, 2026

First Posted (Actual)

August 18, 2026

Study Record Updates

Last Update Posted (Actual)

August 18, 2026

Last Update Submitted That Met QC Criteria

August 12, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26-249

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The datasets generated and/or analyzed during the current study will not be publicly available due to participant privacy but will be available from the corresponding author on reasonable request after the publication of the main trial results. De-identified participant data will be shared subject to approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe